1. Home
  2. IDN vs SGMT Comparison

IDN vs SGMT Comparison

Compare IDN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellicheck Inc.

IDN

Intellicheck Inc.

HOLD

Current Price

$4.33

Market Cap

163.7M

Sector

Technology

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.64

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDN
SGMT
Founded
1994
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
163.7M
169.4M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
IDN
SGMT
Price
$4.33
$6.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$7.33
$26.13
AVG Volume (30 Days)
621.4K
2.8M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
220.00
N/A
EPS
0.03
N/A
Revenue
$4,433,454.00
$2,000,000.00
Revenue This Year
$12.54
N/A
Revenue Next Year
$15.32
N/A
P/E Ratio
$140.00
N/A
Revenue Growth
23.21
N/A
52 Week Low
$3.67
$3.15
52 Week High
$9.08
$11.41

Technical Indicators

Market Signals
Indicator
IDN
SGMT
Relative Strength Index (RSI) 24.47 45.78
Support Level N/A $6.43
Resistance Level $5.34 $6.84
Average True Range (ATR) 0.47 0.51
MACD -0.44 -0.22
Stochastic Oscillator 7.22 9.84

Price Performance

Historical Comparison
IDN
SGMT

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: